Your browser doesn't support javascript.
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
Mwimanzi, Francis; Lapointe, Hope R; Cheung, Peter K; Sang, Yurou; Yaseen, Fatima; Kalikawe, Rebecca; Datwani, Sneha; Burns, Laura; Young, Landon; Leung, Victor; Ennis, Siobhan; Brumme, Chanson J; Montaner, Julio S G; Dong, Winnie; Prystajecky, Natalie; Lowe, Christopher F; DeMarco, Mari L; Holmes, Daniel T; Simons, Janet; Niikura, Masahiro; Romney, Marc G; Brumme, Zabrina L; Brockman, Mark A.
  • Mwimanzi F; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Lapointe HR; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
  • Cheung PK; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Sang Y; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
  • Yaseen F; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Kalikawe R; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Datwani S; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Burns L; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Young L; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
  • Leung V; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
  • Ennis S; Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Brumme CJ; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
  • Montaner JSG; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
  • Dong W; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
  • Prystajecky N; Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Lowe CF; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
  • DeMarco ML; Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Holmes DT; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
  • Simons J; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
  • Niikura M; British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada.
  • Romney MG; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
  • Brumme ZL; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
  • Brockman MA; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Open Forum Infect Dis ; 10(3): ofad073, 2023 Mar.
Artículo en Inglés | MEDLINE | ID: covidwho-2273426
ABSTRACT

Background:

Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection.

Methods:

We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24-98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time.

Results:

Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk.

Conclusions:

Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses.
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas / Variantes Idioma: Inglés Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Artículo País de afiliación: Ofid

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas / Variantes Idioma: Inglés Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Artículo País de afiliación: Ofid